Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs
Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate.
Linear Mode
